These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 34957309)

  • 41. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
    Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Discovery of a multi-target compound for estrogen receptor-positive (ER
    Almeida CF; Teixeira N; Oliveira A; Augusto TV; Correia-da-Silva G; Ramos MJ; Fernandes PA; Amaral C
    Biochimie; 2021 Feb; 181():65-76. PubMed ID: 33278557
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identification of tyrosine kinase inhibitors from Panax bipinnatifidus and Panax pseudoginseng for RTK-HER2 and VEGFR2 receptors, by in silico approach.
    Paul D; Mahanta S; Tag H; Das SK; Das Gupta D; Tanti B; Ananthan R; Das R; Jambhulkar S; Hui PK
    Mol Divers; 2022 Aug; 26(4):1933-1955. PubMed ID: 34554395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Structure-based virtual screening and molecular docking for the identification of potential multi-targeted inhibitors against breast cancer.
    Yousuf Z; Iman K; Iftikhar N; Mirza MU
    Breast Cancer (Dove Med Press); 2017; 9():447-459. PubMed ID: 28652811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Molecular docking and dynamic simulation to identify potential phytocompound inhibitors for EGFR and HER2 as anti-breast cancer agents.
    Prabhavathi H; Dasegowda KR; Renukananda KH; Karunakar P; Lingaraju K; Raja Naika H
    J Biomol Struct Dyn; 2022 Jul; 40(10):4713-4724. PubMed ID: 33345701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular docking and molecular dynamic studies: screening of phytochemicals against EGFR, HER2, estrogen and NF-KB receptors for their potential use in breast cancer.
    Purawarga Matada GS; Dhiwar PS; Abbas N; Singh E; Ghara A; Das A; Bhargava SV
    J Biomol Struct Dyn; 2022 Aug; 40(13):6183-6192. PubMed ID: 33525984
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Unveiling the ESR1 Conformational Stability and Screening Potent Inhibitors for Breast Cancer Treatment.
    Sharma K; Panwar U; Madhavi M; Joshi I; Chopra I; Soni L; Khan A; Bhrdwaj A; Parihar AS; Mohan VP; Prajapati L; Sharma R; Agrawal S; Hussain T; Nayarisseri A; Singh SK
    Med Chem; 2024; 20(3):352-368. PubMed ID: 37929724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
    Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
    Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
    Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
    Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
    O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ERα- breast cancer.
    Liu JC; Voisin V; Bader GD; Deng T; Pusztai L; Symmans WF; Esteva FJ; Egan SE; Zacksenhaus E
    Proc Natl Acad Sci U S A; 2012 Apr; 109(15):5832-7. PubMed ID: 22460789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of small molecule inhibitors of RAD52 for breast cancer therapy: in silico approach.
    Kumar M; Dubey R; Kumar Shukla P; Dayal D; Kumar Chaubey K; Tsai LW; Kumar S
    J Biomol Struct Dyn; 2024 Jun; 42(9):4605-4618. PubMed ID: 37288783
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacoinformatics-based investigation of bioactive compounds of Rasam (South Indian recipe) against human cancer.
    Kalimuthu AK; Panneerselvam T; Pavadai P; Pandian SRK; Sundar K; Murugesan S; Ammunje DN; Kumar S; Arunachalam S; Kunjiappan S
    Sci Rep; 2021 Nov; 11(1):21488. PubMed ID: 34728718
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Repurposing of approved drugs for targeting CDK4/6 and aromatase protein using molecular docking and molecular dynamics studies.
    Yousif FA; Alzain AA; Alraih AM; Ibraheem W
    PLoS One; 2023; 18(9):e0291256. PubMed ID: 37682937
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exploration and evaluation of bioactive phytocompounds against BRCA proteins by
    Prabhavathi H; Dasegowda KR; Renukananda KH; Lingaraju K; Naika HR
    J Biomol Struct Dyn; 2021 Sep; 39(15):5471-5485. PubMed ID: 32643536
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies.
    Rampogu S; Parate S; Parameswaran S; Park C; Baek A; Son M; Park Y; Park SJ; Lee KW
    Comput Biol Chem; 2019 Dec; 83():107113. PubMed ID: 31493740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selection of a GPER1 Ligand via Ligand-based Virtual Screening Coupled to Molecular Dynamics Simulations and Its Anti-proliferative Effects on Breast Cancer Cells.
    Martínez-Muñoz A; Prestegui-Martel B; Méndez-Luna D; Fragoso-Vázquez MJ; García-Sánchez JR; Bello M; Martínez-Archundia M; Chávez-Blanco A; Dueñas-González A; Mendoza-Lujambio I; Trujillo-Ferrara J; Correa-Basurto J
    Anticancer Agents Med Chem; 2018; 18(11):1629-1638. PubMed ID: 29745344
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exploring the Synergistic Mechanism of AP2A2 Transcription Factor Inhibition via Molecular Modeling and Simulations as a Novel Computational Approach for Combating Breast Cancer: In Silico Interpretations.
    Niranjan V; Setlur AS; K C; Kumkum S; Dasgupta S; Singh V; Desai V; Kumar J
    Mol Biotechnol; 2024 Sep; 66(9):2497-2521. PubMed ID: 37747672
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estrogen activation of the mitogen-activated protein kinase is mediated by ER-α36 in ER-positive breast cancer cells.
    Zhang X; Deng H; Wang ZY
    J Steroid Biochem Mol Biol; 2014 Sep; 143():434-43. PubMed ID: 24973581
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ligand and structure based virtual screening of chemical databases to explore potent small molecule inhibitors against breast invasive carcinoma using recent computational technologies.
    Agarwal S; Dixit A; Kashaw SK
    J Mol Graph Model; 2020 Jul; 98():107591. PubMed ID: 32234678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.